An independent validation set of 20 HCC patients with similar clinical features was used to evaluate CTC sensitivity to sorafenib, including ten with < 40% pERK+/pAkt− CTCs and ten with ≥ 40%. The gene discussed is EIF2AK3; the disease is hepatocellular carcinoma.